Журнал кардиореспираторных исследований 2026. №1

Maqola mavzusi

INSULIN RESISTANCE AS A PREDICTOR OF RESTENOSIS AND BLOOD PRESSURE INSTABILITY AFTER PERCUTANEOUS CORONARY INTERVENTION (90-94)

Mualliflar

Tashkenbayeva E.N., Tayyub M., Payzullayeva U.F., Pulatova K.S..

Muassasa

Samarkand State medical university

Annotatsiya

Insulin resistance (IR) is a critical link between metabolic dysfunction and adverse cardiovascular outcomes. This retrospective study (2020– 2026) evaluates the prognostic value of HOMA-IR in predicting in-stent restenosis and blood pressure (BP) instability following percutaneous coronary intervention (PCI). Results indicate that elevated HOMA-IR is an independent predictor of restenosis, increased inflammatory activity, and poor long-term outcomes, regardless of diabetes status. Additionally, IR-related sympathetic hyperactivity contributes to post-PCI hemodynamic instability. Identifying IR as a predictor enhances risk stratification and supports a personalized cardiometabolic approach for PCI patients.

Kalit so'zlar

Insulin resistance; Percutaneous coronary intervention; In-stent restenosis; Blood pressure instability; HOMA-IR; Coronary artery disease; Diabetes mellitus; Endothelial dysfunction; Cardiometabolic risk.

Adabiyotlar

1. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am. 2011;95(5):875–892. 2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for non-insulin-dependent diabetes mellitus, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–194. 3. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 2000;23(1):57–63. 4. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation. 2000;102(1):42–47. 5. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients: increased restenosis, decreased event-free survival. Circulation. 1996;94(8):1818–1825. 6. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–1907. 7. Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiovasc Res. 2014;101(4):552–559. 8. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5–12. 9. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Quarti-Trevano F, et al. Long-term prognostic value of blood pressure variability in the general population. Hypertension. 2007;49(6):1265–1270. 10. Schillaci G, Pucci G, Parati G. Blood pressure variability and organ damage. Hypertension. 2012;60(2):303–308. 11. Ziegler D, Gries FA. Autonomic neuropathy in diabetes mellitus. Diabet Med. 1994;11(3):243–262. 12. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354(5):483–495. 13. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874. 14. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction. Lancet. 2004;364(9438):937–952. 15. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic adults. Diabetes Care. 2003;26(10):2735–2741.